Therapeutic Effects of Clarithromycin and Molnupiravir in Management of COVID-19 Patients

Therapeutic Effects of Clarithromycin Combined with Molnupiravir in Management of Mild to Moderate COVID-19 Hospitalized Patients: a case control study - Therapeutic Effects of Clarithromycin Combined with Molnupiravir in Management of Mild to Moderate COVID-19 Hospitalized Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048841

Enrollment

119

Registered

2022-12-31

Start date

2022-05-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 patients

Interventions

Patients with respiratory symptoms (n=54) received concurrent administration of Clarithromycin (400 mg per day

200 mg twice daily for 3 days), and asymptomatic patients (n=37) received molnupiravir alone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with respiratory symptoms were administered Clarithromycin in combination, and asymptomatic patients were administered molnupiravir alone.

Exclusion criteria

Exclusion criteria: not Mild or moderate patient

Design outcomes

Primary

Measure	Time frame
On the day SARS-CoV-2 positivity was detected, mild or asymptomatic COVID-19 patients were administered molnupiravir for 5 or 7 days, and those with respiratory symptoms were co-administered with CAM for 3 days	—

Secondary

Measure	Time frame
Prognostic effect of combined administration of molnupiravir plus clarithromycin	—

Countries

Japan

Contacts

Public ContactKENJI GONDA

Daido Central Hospital Surgery

gondake@fmu.ac.jp0988690005

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026